Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress

Xu,Renhua; Yuan,Zhenwei; Yang,Lijuan; Li,Lele; Li,Dan; Lv,Changjun

doi:10.3892/or.2017.5793

Inhibition of NAMPT decreases cell growth and enhances susceptibility to oxidative stress

Authors:
- Renhua Xu
- Zhenwei Yuan
- Lijuan Yang
- Lele Li
- Dan Li
- Changjun Lv
View Affiliations

Affiliations: School of Nursing, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Library, Binzhou Medical University, Yantai, Shandong 264003, P.R. China, Cancer Research Institute, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, P.R. China, Department of Respiratory Medicine, Affiliated Hospital of Binzhou Medical University, Binzhou, Shandong 256603, P.R. China
Published online on: July 6, 2017 https://doi.org/10.3892/or.2017.5793
Pages: 1767-1773

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Nicotinamide adenine dinucleotide (NAD) is an essential molecule for living organisms and plays a vital role in aging and age-associated diseases. In eukaryotic cells, cellular NAD is mainly generated by the scavenge pathway in which nicotinamide phosphoribosyltransferase (NAMPT) catalyzes the formation of nicotinamide mononucleotide. Inhibition of NAMPT is a therapeutic strategy for cancer treatment. To explore the effects of NAMPT inhibition on cellular processes, cells were treated with 10 nM FK866, an NAMPT inhibitor, resulting in a decrease in the cellular NAD level, a lower growth rate, and enhanced susceptivity to oxidative stress as compared to the untreated cells. Quantitative proteomics revealed that 325 proteins were downregulated in the FK866-treated cells, and were involved in diverse cellular processes including nucleobase-containing compound metabolic process, protein metabolic process, antioxidant and DNA repair processes. Downregulation of 4 selected proteins was confirmed by western blotting and quantitative PCR. Downregulation of antioxidant proteins GRX1 and catalase, and DNA-repair proteins PCNA and PARP1 contributed to the enhanced susceptibility of FK866-treated cells to oxidative stress. FK866 treatment also caused mitochondrial dysfunction through downregulation of mitochondrial ribosomal proteins. Taken together, these results demonstrate that FK866 treatment efficiently decreases the cellular NAD level and induces autonomous changes in proteostasis, leading to cell growth inhibition and increased susceptibility to oxidative stress.

View Figures

View References

1	Yang Y and Sauve AA: NAD(+) metabolism: Bioenergetics, signaling and manipulation for therapy. Biochim Biophys Acta. 1864:1787–1800. 2016. View Article : Google Scholar : PubMed/NCBI
2	Verdin E: NAD⁺ in aging, metabolism, and neurodegeneration. Science. 350:1208–1213. 2015. View Article : Google Scholar : PubMed/NCBI
3	Imai S and Guarente L: NAD⁺ and sirtuins in aging and disease. Trends Cell Biol. 24:464–471. 2014. View Article : Google Scholar : PubMed/NCBI
4	Viña J, Saez GT, Gambini J, Gomez-Cabrera MC and Borrás C: Role of NAD(+)/NADH redox ratio in cell metabolism: A tribute to Helmut Sies and Theodor Bücher and Hans A. Krebs. Arch Biochem Biophys. 595:176–180. 2016. View Article : Google Scholar : PubMed/NCBI
5	Ying W: NAD⁺/NADH and NADP⁺/NADPH in cellular functions and cell death: Regulation and biological consequences. Antioxid Redox Signal. 10:179–206. 2008. View Article : Google Scholar : PubMed/NCBI
6	Xia W, Wang Z, Wang Q, Han J, Zhao C, Hong Y, Zeng L, Tang L and Ying W: Roles of NAD(+)/NADH and NADP(+)/NADPH in cell death. Curr Pharm Des. 15:12–19. 2009. View Article : Google Scholar : PubMed/NCBI
7	Blander G and Guarente L: The Sir2 family of protein deacetylases. Annu Rev Biochem. 73:417–435. 2004. View Article : Google Scholar : PubMed/NCBI
8	Moazed D: Enzymatic activities of Sir2 and chromatin silencing. Curr Opin Cell Biol. 13:232–238. 2001. View Article : Google Scholar : PubMed/NCBI
9	Denu JM: The Sir 2 family of protein deacetylases. Curr Opin Chem Biol. 9:431–440. 2005. View Article : Google Scholar : PubMed/NCBI
10	Guarente L: Sirtuins and calorie restriction. Nat Rev Mol Cell Biol. 13:2072012.PubMed/NCBI
11	Verdin E, Hirschey MD, Finley LW and Haigis MC: Sirtuin regulation of mitochondria: Energy production, apoptosis, and signaling. Trends Biochem Sci. 35:669–675. 2010. View Article : Google Scholar : PubMed/NCBI
12	Brooks CL and Gu W: How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer. 9:123–128. 2009. View Article : Google Scholar : PubMed/NCBI
13	Yang H, Yang T, Baur JA, Perez E, Matsui T, Carmona JJ, Lamming DW, Souza-Pinto NC, Bohr VA, Rosenzweig A, et al: Nutrient-sensitive mitochondrial NAD⁺ levels dictate cell survival. Cell. 130:1095–1107. 2007. View Article : Google Scholar : PubMed/NCBI
14	Chang HC and Guarente L: SIRT1 mediates central circadian control in the SCN by a mechanism that decays with aging. Cell. 153:1448–1460. 2013. View Article : Google Scholar : PubMed/NCBI
15	Luo X and Kraus WL: On PAR with PARP: Cellular stress signaling through poly(ADP-ribose) and PARP-1. Genes Dev. 26:417–432. 2012. View Article : Google Scholar : PubMed/NCBI
16	Schreiber V, Dantzer F, Ame JC and de Murcia G: Poly(ADP-ribose): Novel functions for an old molecule. Nat Rev Mol Cell Biol. 7:517–528. 2006. View Article : Google Scholar : PubMed/NCBI
17	Braidy N, Guillemin GJ, Mansour H, Chan-Ling T, Poljak A and Grant R: Age related changes in NAD⁺ metabolism oxidative stress and Sirt1 activity in wistar rats. PLoS One. 6:e191942011. View Article : Google Scholar : PubMed/NCBI
18	Prolla TA and Denu JM: NAD⁺ deficiency in age-related mitochondrial dysfunction. Cell Metab. 19:178–180. 2014. View Article : Google Scholar : PubMed/NCBI
19	Mouchiroud L, Houtkooper RH, Moullan N, Katsyuba E, Ryu D, Cantó C, Mottis A, Jo YS, Viswanathan M, Schoonjans K, et al: The NAD(+)/sirtuin pathway modulates longevity through activation of mitochondrial UPR and FOXO signaling. Cell. 154:430–441. 2013. View Article : Google Scholar : PubMed/NCBI
20	Mills KF, Yoshida S, Stein LR, Grozio A, Kubota S, Sasaki Y, Redpath P, Migaud ME, Apte RS, Uchida K, et al: Long-term administration of nicotinamide mononucleotide mitigates age-associated physiological decline in mice. Cell Metab. 24:795–806. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zhang H, Ryu D, Wu Y, Gariani K, Wang X, Luan P, D'Amico D, Ropelle ER, Lutolf MP, Aebersold R, et al: NAD⁺ repletion improves mitochondrial and stem cell function and enhances life span in mice. Science. 352:1436–1443. 2016. View Article : Google Scholar : PubMed/NCBI
22	Fang EF, Kassahun H, Croteau DL, Scheibye-Knudsen M, Marosi K, Lu H, Shamanna RA, Kalyanasundaram S, Bollineni RC, Wilson MA, et al: NAD(+) replenishment improves lifespan and healthspan in ataxia telangiectasia models via mitophagy and DNA repair. Cell Metab. 24:566–581. 2016. View Article : Google Scholar : PubMed/NCBI
23	Camacho-Pereira J, Tarragó MG, Chini CC, Nin V, Escande C, Warner GM, Puranik AS, Schoon RA, Reid JM, Galina A, et al: CD38 dictates age-related NAD decline and mitochondrial dysfunction through an SIRT3-dependent mechanism. Cell Metab. 23:1127–1139. 2016. View Article : Google Scholar : PubMed/NCBI
24	Mei SC and Brenner C: NAD as a genotype-specific drug target. Chem Biol. 20:1307–1308. 2013. View Article : Google Scholar : PubMed/NCBI
25	Chiarugi A, Dölle C, Felici R and Ziegler M: The NAD metabolome - a key determinant of cancer cell biology. Nat Rev Cancer. 12:741–752. 2012. View Article : Google Scholar : PubMed/NCBI
26	Gallí M, Van Gool F, Rongvaux A, Andris F and Leo O: The nicotinamide phosphoribosyltransferase: A molecular link between metabolism, inflammation, and cancer. Cancer Res. 70:8–11. 2010. View Article : Google Scholar : PubMed/NCBI
27	Garten A, Petzold S, Körner A, Imai S and Kiess W: Nampt: Linking NAD biology, metabolism and cancer. Trends Endocrinol Metab. 20:130–138. 2009. View Article : Google Scholar : PubMed/NCBI
28	Hasmann M and Schemainda I: FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis. Cancer Res. 63:7436–7442. 2003.PubMed/NCBI
29	Khan JA, Tao X and Tong L: Molecular basis for the inhibition of human NMPRTase, a novel target for anticancer agents. Nat Struct Mol Biol. 13:582–588. 2006. View Article : Google Scholar : PubMed/NCBI
30	Thakur BK, Dittrich T, Chandra P, Becker A, Kuehnau W, Klusmann JH, Reinhardt D and Welte K: Involvement of p53 in the cytotoxic activity of the NAMPT inhibitor FK866 in myeloid leukemic cells. Int J Cancer. 132:766–774. 2013. View Article : Google Scholar : PubMed/NCBI
31	Thakur BK, Dittrich T, Chandra P, Becker A, Lippka Y, Selvakumar D, Klusmann JH, Reinhardt D and Welte K: Inhibition of NAMPT pathway by FK866 activates the function of p53 in HEK293T cells. Biochem Biophys Res Commun. 424:371–377. 2012. View Article : Google Scholar : PubMed/NCBI
32	Schuster S, Penke M, Gorski T, Gebhardt R, Weiss TS, Kiess W and Garten A: FK866-induced NAMPT inhibition activates AMPK and downregulates mTOR signaling in hepatocarcinoma cells. Biochem Biophys Res Commun. 458:334–340. 2015. View Article : Google Scholar : PubMed/NCBI
33	Cea M, Cagnetta A, Fulciniti M, Tai YT, Hideshima T, Chauhan D, Roccaro A, Sacco A, Calimeri T, Cottini F, et al: Targeting NAD⁺ salvage pathway induces autophagy in multiple myeloma cells via mTORC1 and extracellular signal-regulated kinase (ERK1/2) inhibition. Blood. 120:3519–3529. 2012. View Article : Google Scholar : PubMed/NCBI
34	Billington RA, Genazzani AA, Travelli C and Condorelli F: NAD depletion by FK866 induces autophagy. Autophagy. 4:385–387. 2008. View Article : Google Scholar : PubMed/NCBI
35	Xu R, Tian E, Tang H, Liu C and Wang Q: Proteomic analysis of gossypol induces necrosis in multiple myeloma cells. Biomed Res Int. 2014:8392322014. View Article : Google Scholar : PubMed/NCBI
36	Brigelius-Flohé R and Maiorino M: Glutathione peroxidases. Biochim Biophys Acta. 1830:3289–3303. 2013. View Article : Google Scholar : PubMed/NCBI
37	Brigelius-Flohé R and Kipp A: Glutathione peroxidases in different stages of carcinogenesis. Biochim Biophys Acta. 1790:1555–1568. 2009. View Article : Google Scholar : PubMed/NCBI
38	Novoselov SV, Kryukov GV, Xu XM, Carlson BA, Hatfield DL and Gladyshev VN: Selenoprotein H is a nucleolar thioredoxin-like protein with a unique expression pattern. J Biol Chem. 282:11960–11968. 2007. View Article : Google Scholar : PubMed/NCBI
39	Zhang T, Berrocal JG, Yao J, DuMond ME, Krishnakumar R, Ruhl DD, Ryu KW, Gamble MJ and Kraus WL: Regulation of poly(ADP-ribose) polymerase-1-dependent gene expression through promoter-directed recruitment of a nuclear NAD⁺ synthase. J Biol Chem. 287:12405–12416. 2012. View Article : Google Scholar : PubMed/NCBI
40	Bai P, Cantó C, Oudart H, Brunyánszki A, Cen Y, Thomas C, Yamamoto H, Huber A, Kiss B, Houtkooper RH, et al: PARP-1 inhibition increases mitochondrial metabolism through SIRT1 activation. Cell Metab. 13:461–468. 2011. View Article : Google Scholar : PubMed/NCBI